Announcements Trials
Browse Landscape

Phase

Phase 1/2 1

Status

Unknown 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Gastrointestinal 1

Conditions

Stomach Neoplasms 1Pancreatic Neoplasms 1Colorectal Neoplasms 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Hepatocellular 1

Interventions

pembrolizumab 24Nivolumab 19atezolizumab 9Specimen Handling 7Magnetic Resonance Spectroscopy 7Cyclophosphamide 7durvalumab 5Ipilimumab 5fludarabine 4Trastuzumab 4cemiplimab 3cabozantinib 3avelumab 3Sunitinib 3Biopsy 3ulixertinib 2toripalimab 2tislelizumab 2spartalizumab 2sargramostim 2relatlimab 2palbociclib 2lenvatinib 2epacadostat 2enzalutamide 2cyclopropapyrroloindole 2copanlisib 2budigalimab 2aldesleukin 2X-Rays 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Carcinoma, Hepatocellular × Sensitivity and Specificity × Thoracic × Clear all
NCT02839954 2016-12-06

CAR-pNK Cell Immunotherapy in MUC1 Positive Relapsed or Refractory Solid Tumor

PersonGen BioTherapeutics (Suzhou) Co., Ltd.

Phase 1/2 Unknown
10 enrolled
GastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Carcinoma, Hepatocellular, Pancreatic Neoplasms, Stomach Neoplasms, Colorectal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡